Open more possibilities with the GORE® VIABAHN® Endoprosthesis
Proven across a broad range of complex cases, the versatility of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface* enables you to deliver high patency and durable outcomes to minimize reinterventions. Consider the types of cases you treat and the challenges they present; the GORE® VIABAHN® Endoprosthesis helps you optimize clinical outcomes for your patients.
Superficial femoral artery (SFA)
The GORE® VIABAHN® Endoprosthesis delivers strong clinical performance in the most challenging cases with 75% average primary patency demonstrated across five multicenter, prospective, randomized or single arm studies with an average lesion length of 22 cm and 72% chronic total occlusions (CTOs)1-5
Comparable clinical results to above knee surgical bypass (both prosthetic and native vein)1,6
Excellent patency and durability independent of lesion length1-5
In-stent restenosis (ISR) of the SFA
The GORE® VIABAHN® Endoprosthesis provides durable treatment for complex in-stent restenotic lesions
Ability to cover and seal disease, leading to durable outcomes in long, complex ISR
Iliac Artery
The GORE® VIABAHN® Endoprosthesis is the only self-expanding stent graft indicated to treat iliac lesions
The GORE® VIABAHN® Endoprosthesis family has demonstrated patency that approaches surgical bypass7-9
Popliteal artery aneurysm (PAA)
The GORE® VIABAHN® Endoprosthesis shows strong clinical performance in challenging PAA cases
Endovascular repair of popliteal aneurysms is associated with acceptable long-term patency and a very low risk of limb loss10
* Heparin Bioactive Surface is synonymous with the CBAS Heparin Surface.
1. Reijnen M, van Walraven L, Fritschy W, et al. 1-year results of a multicenter, randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. Journal of Cardiovascular Interventions 2107;10(22):2320-2331.
2. Ohki T, Kichikawa K, Yokoi H, et al. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. Journal of Vascular Surgery 2017;66(1):130-142.e1.
3. Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin-bonded Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. Journal of Vascular & Interventional Radiology 2013;24(2):165173.
4. Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR Trial. Cardiovascular & Interventional Radiology 2015;38(1):25-32.
5. Zeller T, Peeters P, Bosiers M, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm Trial. Journal of Endovascular Therapy 2014;21(6):765-774.
6. McQuade K, Gable D, Pearl G, Theune B, Black S. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. Journal of Vascular Surgery 2010;52(3):584-591.
7. Lammer J, Dake MD, Bleyn J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent graft. Radiology 2000;217(1):95-104.
8. Bismuth J, Gray BH, Holden A, Metzger C, Panneton J; VBX FLEX Study Investigators. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. Journal of Endovascular Therapy 2017;24(5):629-637. http://journals.sagepub.com/doi/full/10.1177/1526602817720463
9. Indes JE, Pfaff MJ, Farrokhyar F, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. Journal of Endovascular Therapy 2013;20(4):443-455.
10. Golchehr B, Zeebregts CJ, Reijnen MMPJ, Tielliu IFJ. Long-term outcome of endovascular popliteal artery aneurysm repair. Journal of Vascular Surgery 2018;67(6):1797-1804.